Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Histologically or cytologically confirmed squamous cell carcinoma of the oropharynx or unknown primary that is HPV 16 positive as determined by ISH and p16 positive as determined by IHC.~* Stage 3 or 4 disease without evidence of distant metastases~* At least one evaluable or uni- or bi-dimensionally measurable lesion by RECIST 1.1 criteria~* 18 years of age or older~* No previous surgery, radiation therapy or chemotherapy for SSCHN is allowed at time of study entry~* ECOG Performance Status of 0 or 1~* No active alcohol addiction~* Adequate bone marrow, hepatic and renal function as defined in the protocol~* Women of child-bearing potential must have a negative pregnancy test within 7 days of starting treatment~Exclusion Criteria~* Pregnant or breast feeding women or women and men of childbearing potential not willing to use adequate contraception while on treatment and for at least 3 months after~* Previous or current malignancies at other sites~* Symptomatic peripheral neuropathy of grade 2 or greater~* Symptomatic altered hearing greater than grade 2~* Other serious illnesses or medical conditions~* Patients that have experienced an involuntary weight loss of more than 25% of their body weight in the 2 months preceding study entry~* Concurrent treatment with any other anticancer therapy~* Participation in an investigational trial within 30 days of study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TPF Induction Chemotherapy followed by Chemoradiotherapy (Type: EXPERIMENTAL): Patients received 3 cycles (21 days each) of TPF induction chemotherapy: docetaxel 75 mg/m2 IV day 1; cisplatin 100 mg/m2 IV day 1 (carboplatin substitute permitted); 5-FU 1000 mg/m2/day IV pump continuous days 1-4. Concurrent chemoradiotherapy followed 4-6 weeks after day 1 of cycle 3 TPF induction: cetuximab 400 mg/m2 IV loading dose 1 week prior and 250 mg/m2 IV weekly (panitumumab substitute permitted); carboplatin AUC 1.5 (Calvert formula) IV weekly; Intensity modulated radiation therapy (IMRT)-response based dosing for 6-7 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).